Sahota, Surinder - University of Southampton

个人简介

Dr Surinder Sahota is Reader in Immunogenetics within Medicine at the University of Southampton, and was appointed to this position in 2006. In the Faculty, Dr Sahota is a Principal Investigator in the Cancer Sciences Academic Unit. He is best known for exploiting immunogenetic imprints in the tumour genome to define clonal origins of the B-cell neoplasm multiple myeloma (MM), and its benign precursor disease monoclonal gammopathy of undetermined significance (MGUS). Dr Sahota has utilised this and other molecular and cellular immunological approaches to author more than 70 journal articles in defining tumour origins and behaviour in B-cell malignancy. He is also Co-ordinator and work-package leader for large EU-wide networks of investigators probing MM and lymphoma disease, and has led or jointly led a number of bids under the FP6, FP7 and more recently the H2020 programmes to seek funding from the European Commission. Successfully funded networks have included MSCNET (FP6; Euro 3 million) and OVER-MyR (FP7; Euro 3 million), both investigating MM disease. Dr Sahota also peer-reviews for many of the leading national and international cancer grant funding bodies, including in the EU and USA. In 2015, Dr Sahota joined the Scientific Advisory Committee of the International Waldenstrom’s macroglobulinemia (WM) Foundation (USA). In the UK, he is a member of the WMUK Doctors Forum Advisory Committee and of the WM GECIP on the Genome England 100,000 Genomes Project. Previously he was a member of the national UK Myeloma Forum Scientific Committee. Dr Sahota has also been a member of the Advisory Scientific Boards of International Workshops on MM and WM, and is advisor to national biotech boards delivering conferences on Applications of Next Generation DNA Sequencing in Cancer.

研究领域

My interests lie in seeking evidence for genomic changes acquired somatically in malignant B-cells that inform disease pathogenesis and that can be exploited to test functional outcomes in tumour cells in promoting survival. I am also interested in exploiting molecular and cellular features of malignant B-cells as targets for immunotherapy, specifically as targets for DNA vaccines.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma - Noble, Fergus, Mellows, Toby, McCormick Matthews, Leo H., Bateman, Adrian, Harris, Scott, Underwood, Tim, Byrne, James P., Bailey, Ian S., Sharland, Donna M., Kelly, Jamie J., Primrose, John N., Sahota, Surinder S., Bateman, Andrew R., Thomas, Gareth J and Ottensmeier, Christian H. Published:2016Publication:Cancer Immunology ImmunotherapyVolume:65, (6)Page Range:651-662doi:10.1007/s00262-016-1826-5PMID:27020682 Exome sequencing in classic hairy cell leukaemia reveals widespread variation in acquired somatic mutations between individual tumours apart from the signature BRAF V(600)E lesion - Weston-Bell, Nicola J., Tapper, Will, Gibson, Jane, Bryant, Dean, Moreno, Yurany, John, Melford, Ennis, Sarah, Kluin-Nelemans, Hanneke C., Collins, Andrew R. and Sahota, Surinder S. Published:2016Publication:PLoS ONEVolume:11, (2)Page Range:1-14doi:10.1371/journal.pone.0149162PMID:26871591 Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma - Cowan, Graeme, Weston-Bell, Nicola J., Bryant, Dean, Seckinger, Anja, Hose, Dirk, Zojer, Niklas and Sahota, Surinder S. Published:2015Publication:Oncotarget PMID:25929340 Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes - Weston-Bell, Nicola J., Forconi, Francesco, Kluin-Nelemans, Hanneke C. and Sahota, Surinder S. Published:2013Publication:PLoS ONEVolume:9, (1)Page Range:e86556doi:10.1371/journal.pone.0086556PMID:24497953